Ceruloplasmin and iron in Alzheimer's disease and Parkinson's disease: a synopsis of recent studies.
Cast your vote
You can rate an item by clicking the amount of stars they wish to award to this item.
When enough users have cast their vote on this item, the average rating will also be shown.
Your vote was cast
Thank you for your feedback
Thank you for your feedback
MetadataShow full item record
CitationNeuropsychiatr Dis Treat 2012, 8:515-21
AbstractCeruloplasmin (Cp) concentration and oxidative activity in serum are lowered in Parkinson's disease (PD). In most PD patients, iron increases in the substantia nigra in the midbrain. In PD, the low Cp concentration and activity in serum and the high iron amounts in the substantia nigra appears to be correlated. An hereditary background is common in PD and variations in the Cp gene that have been found in PD are associated with high iron levels in the substantia nigra. Variations in Cp synthesis and in the incorporation of copper into the Cp molecule are essential features of PD. In Alzheimer's disease (AD), the Cp activity in serum is lowered but not the concentration, except in the advanced stages of the disease. Generally, iron is not increased in the AD brain. In the AD brain, iron accumulates in neuritic plaques and in neurofibrillary tangles. There is also increased risk of iron-mediated tissue damage, which may possibly be counteracted by Cp. At the same time, the AD brain is short in copper, which presumably results in the deficient activity of many copper enzymes in the brain, in addition to Cp. Lowered Cp activity in serum most likely stems from lessened incorporation of copper in the Cp molecule and similar incorporation defects might also apply to other copper enzymes in AD.
DescriptionTo access publisher full text version of this article. Please click on the hyperlink in Additional Links field.
RightsArchived with thanks to Neuropsychiatric disease and treatment
- [Ceruloplasmin (Cp) and iron in connection with Parkinson's disease (PD) and Alzheimer's disease (AD)].
- Authors: Johannesson T, Kristinsson J, Torsdottir G, Snaedal J
- Issue date: 2012 Oct
- Ceruloplasmin, a Potential Therapeutic Agent for Alzheimer's Disease.
- Authors: Zhao YS, Zhang LH, Yu PP, Gou YJ, Zhao J, You LH, Wang ZY, Zheng X, Yan LJ, Yu P, Chang YZ
- Issue date: 2018 May 10
- Ceruloplasmin immunoreactivity in neurodegenerative disorders.
- Authors: Loeffler DA, Sima AA, LeWitt PA
- Issue date: 2001 Aug
- Ceruloplasmin and iron proteins in the serum of patients with Alzheimer's disease.
- Authors: Torsdottir G, Kristinsson J, Snaedal J, Jóhannesson T
- Issue date: 2011 Jan
- Ceruloplasmin activity and iron chelation treatment of patients with Parkinson's disease.
- Authors: Grolez G, Moreau C, Sablonnière B, Garçon G, Devedjian JC, Meguig S, Gelé P, Delmaire C, Bordet R, Defebvre L, Cabantchik IZ, Devos D
- Issue date: 2015 May 6